Steven Nagelberg, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1619917267
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 56.4% of the total. Reporting peaked in 2019 at $3,194 and has fallen 57.6% since, to $1,356 in 2025.
Across 83 payments — averaging $62.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Medtronic$1K
- Novo Nordisk$250
- Insulet Corporation$99
- Sanofi-aventis U.S. LLC$89
- Dexcom, Inc.$88
- plus $273 from 10 others
Across 1,154 payments — averaging $415.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$435K
- Eli Lilly$40K
- Merck$3K
What the payments were for
- Consulting fees$3757%
- Speaking & faculty fees$2,34045%
- Travel & lodging$90117%
- Food & beverage$1,51829%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $2,909 |
| Medtronic(2 entities) | 32 | $1,449 |
| Novo Nordisk | 14 | $250 |
| Insulet Corporation | 4 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Dexcom, Inc. | 4 | $88 |
| Tandem Diabetes Care, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $42 |
| Abbott | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Senseonics, Incorporated | 1 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| AbbVie | 1 | $20 |
| AstraZeneca | 1 | $13 |
| BETA Bionics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$2,831
- MINIMED 780G$820
How this compares
$5,156 in reported general payments places this provider in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 309 | $516,492 |
| MounjaroTirzepatide | 301 | $427,904 |
| JardianceEmpagliflozin | 277 | $373,645 |
| FarxigaDapagliflozin Propanediol | 129 | $140,733 |
| Tresiba Flextouch U-100Insulin Degludec | 166 | $136,956 |
| TrulicityDulaglutide | 70 | $103,469 |
| RybelsusSemaglutide | 38 | $86,365 |
| JanuviaSitagliptin Phosphate | 79 | $82,403 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $66,136 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $55,812 |
| Novolog FlexpenInsulin Aspart | 155 | $55,193 |
| JanumetSitagliptin Phos/Metformin Hcl | 47 | $50,861 |
| SomavertPegvisomant | 12 | $50,710 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $50,666 |
| ProliaDenosumab | 29 | $49,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $250 | $625,846395 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $36 | $559,242429 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $383,478288 claims |
| AstraZenecaFarxiga | $13 | $140,733129 claims |
| AmgenProlia | $23 | $49,77829 claims |
| Johnson & JohnsonInvokana | $2,909 | $27,33417 claims |
| AbbVieSynthroid | $20 | $22,182276 claims |
| Sanofi-aventis U.S. LLCLantus | $89 | $6,69737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.